The immunologic checkpoint inhibitors avelumab and pemrolizomab show promise in patients with metastatic breast cancer; a trastuzumab-based, nonanthracycline regimen yields cardiac safety benefits in early HER2-positive disease; and the oral tyrosine kinase inhibitor neratinib delivers consistent disease-free survival at 3 years: Bruce Jancin and Susan London report from the 2015 annual meeting of the San Antonio Breast Cancer Symposium.
Click on the PDF icon at the top of this introduction to read the full article.